Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1600-065x.1992.tb01421.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-CD4 monoclonal antibody prevents chronic graft-versus-host disease in mice by inducing immune tolerance of CD8 T cells and alleviating thymus injury.
Front Immunol
January 2025
Department of Hematology, Changhai Hospital, The Second Military Medical University, Shanghai, China.
Background: Chronic graft-versus-host disease (cGVHD) manifests with characteristics of autoimmune disease with organs attacked by pathogenic helper T cells. Recent studies have highlighted the role of T cells in cGVHD pathogenesis. Due to limited understanding of underlying mechanisms, preventing cGVHD after allogenic hematopoietic cell transplantation (HCT) has become a major challenge.
View Article and Find Full Text PDFSustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir.
Nat Med
January 2025
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
The clinical management of people with multidrug-resistant (MDR) human immunodeficiency virus (HIV) remains challenging despite continued development of antiretroviral agents. A 58-year-old male individual with MDR HIV and Kaposi sarcoma (KS) was treated with a new antiretroviral regimen consisting of anti-CD4 domain 1 antibody UB-421 and capsid inhibitor lenacapavir. The individual experienced delayed but sustained suppression of plasma viremia and a substantial increase in the CD4 T cell count.
View Article and Find Full Text PDFDepletion of conventional CD4 T cells is required for robust priming and dissemination of tumor antigen-specific CD8 T cells in the setting of anti-CD4 therapy.
J Immunother Cancer
November 2024
Department of Microbiology and Immunology, Dartmouth College Geisel School of Medicine, Lebanon, New Hampshire, USA
Background: Overcoming immune suppression is a major barrier to eliciting potent CD8 T cell responses against cancer. Treatment with anti-CD4 monoclonal antibody is an effective means for eliminating CD4Foxp3 regulatory (Treg) cells in preclinical models and has also demonstrated efficacy in early clinical trials. However, the underlying basis for treatment efficacy, more specifically the implications of codepleting other CD4-expressing cell compartments in tumor-bearing hosts, is not well understood.
View Article and Find Full Text PDFSafety of teplizumab in patients with high-risk for diabetes mellitus type 1: A systematic review.
World J Diabetes
August 2024
Anesthesiology, Mayo Clinic, Rochester, MN 55905, United States.
Background: The incidence of diabetes mellitus type 1 (DM1) has been rising worldwide because of improvements in diagnostic techniques and improved access to care in countries with lower socioeconomic status. A new anti-CD4 antibody, Tep-lizumab, has been shown to delay the progression of DM1 and is the only medication approved for this indication. However, more information is needed about the safety profile of this drug.
View Article and Find Full Text PDFHighly potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alteration.
Nat Commun
August 2024
Center for Public Health Research, Medical School, Nanjing University, Nanjing, P.R. China.
Article Synopsis
- Despite progress in HIV treatment through antiretroviral therapy (ART), limitations like lifelong medication and viral resistance drive the need for new approaches.
- Ibalizumab is currently the only approved CD4-specific antibody, and research into anti-CD4 nanobodies, particularly one called Nb457 from an alpaca, shows promise for better efficacy against HIV-1.
- Nb457, especially in its engineered trimeric form, not only surpasses Ibalizumab in effectiveness but also demonstrates significant therapeutic benefits in mouse models, indicating potential for future clinical applications.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!